Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1741 to 1755 of 8211 results

  1. Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over [TSID10761]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years [TSID10350]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. TVB-009 (denosumab biosimilar) for treating postmenopausal osteoporosis in people aged 60 to 90 [TSID11807]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer [TSID5462]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]

    Awaiting development Reference number: GID-TA11560 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]

    Awaiting development Reference number: GID-TA11467 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development Reference number: GID-NG10404 Expected publication date: TBC

    NICE guideline
    In development

  12. CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210]

    Awaiting development Reference number: GID-TA11182 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Prolonged-release diazoxide choline for treating Prader-Willi syndrome [ID1389]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Natural Cycles for monitoring fertility

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation